Decades-Old Drug Delivers New Hope

older man in a wheelchair looking out a bright window — Photo: wavebreakmedia / Shutterstock

A cheap, decades-old antidepressant just became one of the first drugs to show real, measured relief for long COVID’s crushing fatigue — and it did so in a government and health system that still has no clear plan for millions of sufferers.

Story Snapshot

Fluvoxamine, a common antidepressant, modestly reduced long COVID fatigue in a gold-standard clinical trial.
Benefits on fatigue and quality of life lasted at least a month after patients stopped taking the drug.
Experts call the results encouraging but warn the effect is modest and not a cure-all.
The study highlights how private researchers, not government, are leading the search for long COVID treatments.

Major Trial Finds Fatigue Relief With Common Antidepressant

Researchers in Brazil, Canada, and the United States ran a randomized, placebo-controlled trial on adults with long COVID and severe fatigue. They tested fluvoxamine, a low-cost antidepressant that has been used for decades to treat obsessive-compulsive disorder and depression. Patients took the drug for 60 days. Fatigue was measured with a seven-point scale. People on fluvoxamine reported lower fatigue than those on placebo at day 60 and again at day 90, one month after stopping the drug. The study was published in Annals of Internal Medicine, a top medical journal.

The size of the effect was not huge but was clear. At day 60, fluvoxamine reduced fatigue by about 0.43 points more than placebo on the seven-point scale. By day 90, the difference was about 0.58 points. On this scale, a change of around half a point can be noticeable in daily life, even if it does not restore full health. The trial’s analysis suggested a 99 percent chance that fluvoxamine really worked better than placebo, rather than the result being a fluke. That level of certainty is rare in long COVID research.

Quality of Life Gains and Safety Profile

Patients who took fluvoxamine did not just feel less tired; they also reported better quality of life. More people on the drug met the study’s definition of “recovery,” meaning their fatigue score dropped below three. These gains matter because many long COVID patients say relentless exhaustion keeps them from working, caring for family, or even handling basic chores. Serious side effects were uncommon, and fluvoxamine had fewer adverse events overall than metformin or placebo in the same trial. That safety record is important for a drug that might be used widely.

The trial also tested metformin, a diabetes drug some hoped would help long COVID, but it showed no meaningful benefit for fatigue beyond a brief, modest improvement. That contrast put more attention on fluvoxamine as a rare bright spot. Still, experts urge caution. A medical adviser for a leading patient group noted that many people with long COVID improve somewhat over time on their own and said the results should be viewed carefully, not as proof of a simple fix. This matches a broader pattern where new long COVID drugs show small gains, not dramatic turnarounds.

Where This Fits in the Bigger Long COVID Fight

This trial lands in a field where millions are desperate, but official answers remain weak. About 1 to 5 percent of adults worldwide are thought to have long COVID symptoms, with fatigue at the top of the list. A major review of clinical trials found several drugs that helped some symptoms, yet the studies were small and hard to generalize. Another large trial of common drugs like antihistamines and a prescription anti-inflammatory found only small benefits for long COVID fatigue. Across all this work, researchers say there is still no standardized, guideline-approved drug treatment for long COVID.

‼️Common antidepressant may ease long COVID’s crushing fatigue

A low-cost antidepressant may offer new hope for people struggling with long COVID fatigue. In a randomized clinical trial involving 399 adults, fluvoxamine significantly reduced fatigue and improved quality of life…

— Martha-JD, MBA, PCC-😷🇺🇦 (@mryoung151) July 19, 2026

Fluvoxamine has appeared in COVID research before. Earlier studies suggested it could reduce the chance of serious illness during active infection and might lower the risk of later fatigue. A recent overview concluded that antidepressants, especially fluvoxamine, show promising signs in preventing severe COVID-19 and long COVID, but the evidence is not yet strong enough to rewrite care guidelines. The new fatigue trial adds one of the clearest signals so far that fluvoxamine can help people already living with long COVID, not just those trying to avoid it.

A Ray of Hope Amid System Failures and Shared Frustration

For Americans watching this from the outside, the story hits a nerve that crosses party lines. Long COVID patients often feel ignored by a federal government that still moves slowly after years of warnings. Many see a system that can spend trillions, yet cannot deliver clear care for people too exhausted to work, even while they face rising costs and shrinking support. Conservatives blame bureaucracy, waste, and elites protecting their own careers. Liberals blame underfunded safety nets and a health system tilted toward profit. Both sides see ordinary patients stuck in the middle.

Fluvoxamine’s modest success shows that progress is possible when researchers push ahead, even without a grand federal plan. But it also underscores how fragile that progress is. One positive trial in Brazil does not guarantee access, insurance coverage, or wise use in clinics across the United States. Doctors need more data on who benefits most, how long treatment should last, and how to balance risks and gains. Patient advocates warn against overselling any single drug, yet they also know that even a half-point drop in fatigue can be the difference between staying in bed and making it through a workday.

What Comes Next for Patients and Policy

Large platform trials for long COVID, including some based in the United States, are now testing multiple drugs at once to speed up answers. These studies aim to find out not just whether a drug works, but for which subgroups and at what stage of illness. Fluvoxamine is one candidate among many. If its benefits are confirmed in other countries and age groups, it could become one of the first widely available tools doctors can offer for long COVID fatigue. That would be a small but real win in a space filled mostly with uncertainty and waiting.

Still, the deeper concern remains: why did it take six years after the pandemic began for patients to see even modest, trial-proven relief for one core symptom? Families who have watched loved ones lose jobs, savings, and health to long COVID may see this news as proof that science can move, even when government drags. They may also see it as one more warning that, in a system run by competing elites and slow agencies, life-changing answers often come late and in small steps, leaving citizens to fight for every inch of recovery.